Dariohealth Stock News

DarioHealth Corp (NASDAQ:DRIO ) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Glenn Garmont - LifeSci Advisors Erez Raphael - CEO & Director Richard Anderson - Presi

Dario Health (DRIO) Poised to Inflect Upon Full Launch of National Health Plan - Fundamentals: Company positioned to avoid dilutive financing after recent $50M credit facility with OrbiMed - Catalys

Cowen & Co. has decided to maintain its Outperform rating of DarioHealth (NASDAQ:DRIO) and raise its price target from $14.00 to $18.00. Shares of DarioHealth are trading up 5.8% over the last 24 hour

Upgrades B of A Securities upgraded the previous rating for Ritchie Bros Auctioneers Inc (NYSE:RBA) from Underperform to Neutral. In the first quarter, Ritchie Bros Auctioneers showed an EPS of $0.46,

DarioHealth Corp. (NASDAQ:DRIO ) Q1 2022 Earnings Conference Call May 12, 2022 8:30 AM ET Company Participants Glenn Garmont - Investor Relations Erez Raphael - Chief Executive Officer Rick Anderson -

DarioHealth's (DRIO) CEO Erez Raphael on Q4 2021 Results - Earnings Call Transcript

Image sourced from Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. DarioHealth Corp. (NASDAQ: DRIO ) announced that it has entered into a strategic agreement with Sanofi U.S., an innovative global healthcare company. The multi-year, $30 million-dollar agreement, which is subject to certain contingencies, will help accelerate commercial adoption of Dario''s full suite of digital therapeutics and drive the expansion of digital health solutions on the Dario platform. Dario and Sanofi will collaborate on promoting the Dario multi-condition digital therapeutics solution, significantly increasing Dario''s sales reach in the health plan market and selectively in the employer channel. In addition, the agreement calls for Dario and Sanofi to develop new … Full story available on Benzinga.com

DarioHealth (DRIO) signed a $30M strategic agreement with Sanofi U.S

DarioHealth (DRIO) is rising 8.9% premarket Tuesday after the firm entered into definitive agreements with certain institutional investors to purchase an aggregate of ~5,342,013 shares…

Image provided by Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Musculoskeletal conditions including injuries, age-related degeneration, movement disorders, and chronic pain affect over 126 million Americans and cost about $213 billion each year to treat. The massive space includes common problems like back pain, arthritis, gout, and osteoporosis among others where treatment can get prohibitively expensive because it often requires long-term or ongoing care. Without physical therapy, pain management, and other treatments aimed at either reducing pain or restoring functionality to the affected area, temporary injuries can turn into permanent disabilities and chronic conditions can worsen at a faster rate. DarioHealth Corp. (NASDAQ: DRIO ) is one example of a company working to address the need for an effective, affordable, and accessible solution ever since its acquisition of Upright Technologies in January 2021.

NEW YORK , Feb. 8, 2022 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO ), a leader in the global digital therapeutics (DTx) market, today announced several new contracts to deliver its digital therapeutics solutions for four new employers. The new accounts are expected to launch during the first and second quarters of 2022. The new clients include a northeast regional employer contracted for Dario''s diabetes solution and three employers - including two educational organizations and a regional professional services firm - launching with Dario''s behavioral health solution. Dario closed 2021 with a total of 54 new contracts in its first full year of selling digital therapeutics in the business-to-business market. The company now has a range of health plans, providers and employers taking advantage of its digital therapeutics platform designed to address the most common chronic conditions: diabetes, hypertension, weight management, musculoskeletal, and behavioral health. "2022 is off to a strong start as Dario continues to experience quick growth with a total of seven new contracts in January 2022 .

DarioHealth (DRIO) entered into an agreement to purchase all of the right, title and interest in certain assets of Physimax Technologies, provider of computer vision

Equities research analysts expect that DarioHealth Corp. (NASDAQ:DRIO) will post earnings of ($1.13) per share for the current quarter, according to Zacks. Two analysts have issued estimates for DarioHealths earnings. The highest EPS estimate is ($1.01) and the lowest is ($1.31). DarioHealth posted earnings of ($1.06) per share during the same quarter last year, which []

Inari Medical (NASDAQ:NARI) and DarioHealth (NASDAQ:DRIO) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends and risk. Earnings & Valuation This table compares Inari Medical and DarioHealths revenue, earnings per share and valuation. Gross []